Our portfolio

Built on the principles of speed, scale and equitable access, CEPI is supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches. Including Bio E, CEPI has invested in 12 vaccine candidates, ten of which are still in development.

In addition to COVID-19, CEPI's priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine development against unknown pathogens (Disease X).

PRODUCT DEVELOPERS
  • All
  • Auro Vaccines & PATH
  • Biological E Limited
  • Clover Biopharmaceuticals
  • Colorado State University
  • CureVac
  • Emergent Biosolutions & PATH
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • Institut Pasteur, Themis Bioscience, University of Pittsburgh
  • International AIDS Vaccine Initiative
  • International Vaccine Institute and Bharat Biotech
  • Janssen Vaccines & University of Oxford
  • Moderna, Inc.
  • Novavax, Inc.
  • Public Health Vaccines
  • SK bioscience
  • Themis Bioscience
  • University of Hong Kong
  • University of Oxford and Astrazeneca
  • University of Queensland
  • University of Tokyo
  • Valneva SE
  • VBI Vaccines
  • Wageningen Bioveterinary Research
DISEASE
  • All
  • Chikungunya
  • COVID-19
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rift Valley Fever
VACCINE TYPE
  • All
  • ChAdOx1
  • Enveloped virus like particle (eVLP)
  • HeV-sG-V vaccine
  • Inactivated Whole Virion vaccine
  • Live attenuated vaccine
  • Measles vector
  • Nucleic acid
  • Protein Antigen
  • Recombinant protein
  • Recombinant protein nanoparticle technology
  • Recombinant viral vector
  • S-Trimer vaccine
PHASE
  • All
  • Development Discontinued
  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase III - Authorised for use in multiple countries
  • Phase III - WHO EUL granted
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['funding_value'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result